HomeCompareASCLF vs JEPI

ASCLF vs JEPI: Dividend Comparison 2026

ASCLF yields 110.50% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASCLF wins by $5.90M in total portfolio value
10 years
ASCLF
ASCLF
● Live price
110.50%
Share price
$1.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$2,132,830.87
Full ASCLF calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — ASCLF vs JEPI

📍 ASCLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASCLFJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASCLF + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASCLF pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASCLF
Annual income on $10K today (after 15% tax)
$9,392.27/yr
After 10yr DRIP, annual income (after tax)
$1,812,906.24/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, ASCLF beats the other by $1,811,606.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASCLF + JEPI for your $10,000?

ASCLF: 50%JEPI: 50%
100% JEPI50/50100% ASCLF
Portfolio after 10yr
$2.98M
Annual income
$1,067,179.75/yr
Blended yield
35.82%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASCLF buys
0
JEPI buys
0
No recent congressional trades found for ASCLF or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASCLFJEPI
Forward yield110.50%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$5.93M$29.0K
Annual income after 10y$2,132,830.87$1,528.62
Total dividends collected$5.35M$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ASCLF vs JEPI ($10,000, DRIP)

YearASCLF PortfolioASCLF Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$21,750$11,049.72$11,260$840.19+$10.5KASCLF
2$45,733$22,460.60$12,641$907.94+$33.1KASCLF
3$93,072$44,137.91$14,150$978.20+$78.9KASCLF
4$183,537$83,949.70$15,795$1,050.85+$167.7KASCLF
5$351,102$154,717.47$17,584$1,125.74+$333.5KASCLF
6$652,287$276,608.54$19,526$1,202.74+$632.8KASCLF
7$1,178,220$480,272.57$21,628$1,281.69+$1.16MASCLF
8$2,071,454$810,758.34$23,898$1,362.43+$2.05MASCLF
9$3,548,616$1,332,160.25$26,347$1,444.79+$3.52MASCLF
10$5,929,850$2,132,830.87$28,982$1,528.62+$5.90MASCLF

ASCLF vs JEPI: Complete Analysis 2026

ASCLFStock

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Full ASCLF Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this ASCLF vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASCLF vs SCHDASCLF vs OASCLF vs KOASCLF vs MAINASCLF vs JEPQASCLF vs XYLDASCLF vs DIVOASCLF vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.